Challenges to management of pain in sickle cell disease by Julie Kanter

Get full text

48847 Assessing Transition Outcomes in Sickle Cell Disease (SCD) Prior To Implementation of A Formal Transition Program by Sydney Sheppard, Julie Kanter

Get full text

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease by Ifeyinwa Osunkwo, Deepa Manwani, Julie Kanter

Get full text

High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study by Julie Kanter, Menaka Bhor, Xin Li, Frank Li, Jincy Paulose

Get full text

Current Methods of Newborn Screening Follow-Up for Sickle Cell Disease Are Highly Variable and without Quality Assurance: Results from the ENHANCE Study by Najibah Galadanci, Shannon Phillips, Alyssa Schlenz, Nataliya Ivankova, Julie Kanter

Get full text

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH S... by Raffaella Colombatti, Julie Kanter, Eric Wu, Leila J. Clay, Andrew Campbell

Get full text

Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study by Najibah A. Galadanci, Walter Johnson, April Carson, Gerhard Hellemann, Virginia Howard, Julie Kanter

Get full text

Validation of a Low-Cost Paper-Based Screening Test for Sickle Cell Anemia. by Nathaniel Z Piety, Xiaoxi Yang, Julie Kanter, Seth M Vignes, Alex George, Sergey S Shevkoplyas

Get full text

Identified barriers and facilitators to stroke risk screening in children with sickle cell anemia: results from the DISPLACE consortium by Shannon M. Phillips, Alyssa M. Schlenz, Martina Mueller, Cathy L. Melvin, Robert J. Adams, Julie Kanter

Get full text

An unusual ultrasound appearance of renal hemosiderosis in acute sickle cell nephropathy by Madison Kocher, MD, Iris Martin, MD, Katherine Twombley, MD, Julie Kanter, MD, Sherron Jackson, MD, Sally Self, MD, Jeanne Hill, MD

Get full text

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS by Miguel Abboud, Julie Kanter, Kwaku Marfo, Charmaine Anthony, Jeremie Lincy, Michele Nassin, Vikas Joshi, Andreas Brueckner, Deborah Keefe, Kenneth I. Ataga

Get full text

Newborn Screening for Sickle Cell Disease in St. Vincent and the Grenadines: Results of a Pilot Newborn Screening Program by Shelly-Ann Williams MD, Beneka Browne-Ferdinand MD, Ynolde Smart SCM, PHN, Kristen Morella MPH, Susan G. Reed DDS, DrPH, Julie Kanter MD

Get full text

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study by Julie Kanter, Sarah Mennito, Santosh M. Nair, Deepa Manwani, Abdullah Kutlar, Nirmish Shah, Deborah Keefe, Hariprasad Madhamshetty, Michele Nassin, Evgeniya Reshetnyak, Anisha E. Mendonza, Darla Liles

Get full text

Perspectives of individuals with sickle cell disease on barriers to care. by Shannon Phillips, Yumei Chen, Rita Masese, Laurence Noisette, Kasey Jordan, Sara Jacobs, Lewis L Hsu, Cathy L Melvin, Marsha Treadwell, Nirmish Shah, Paula Tanabe, Julie Kanter

Get full text

Perspectives of individuals with sickle cell disease on barriers to care by Shannon Phillips, Yumei Chen, Rita Masese, Laurence Noisette, Kasey Jordan, Sara Jacobs, Lewis L. Hsu, Cathy L. Melvin, Marsha Treadwell, Nirmish Shah, Paula Tanabe, Julie Kanter

Get full text

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS ST... by Matthew Heeney1, David Rees, Mariane de Montalembert, Isaac Odame, Yasser Wali, Sarfaraz Sayyed, Velusamy Shanmuganathan Muthusamy, Anisha E. Mendonza, Michele Nassin, Deborah Keefe, Julie Kanter

Get full text

Barriers to Pediatric Sickle Cell Disease Guideline Recommendations by Michael D. Cabana MD, MPH, Julie Kanter MD, Anne M. Marsh MD, Marsha J. Treadwell PhD, Michael Rowland MPH, Peggy Stemmler MD, Naomi S. Bardach MD, MAS

Get full text

Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers i... by Robert Gibson, Jane S Hankins, Matthew P Smeltzer, Kristen E Howell, Marsha Treadwell, Liliana Preiss, Allison A King, Jeffrey A Glassberg, Paula Tanabe, Sherif M Badawy, Lisa DiMartino, Julie Kanter, Lisa M Klesges

Get full text

What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease. by Andrea E Lamont, Lewis L Hsu, Sara Jacobs, Robert Gibson, Marsha Treadwell, Yumei Chen, Richard Lottenberg, Kathleen Axelrod, Taniya Varughese, Cathy Melvin, Sharon Smith, Ifeanyi Beverly Chukwudozie, Julie Kanter, Sickle Cell Disease Implementation Consortium

Get full text

Evaluating the Discriminatory Ability of the Sickle Cell Data Collection Program’s Administrative Claims Case Definition in Identifying Adults With Sickle Cell Disease: Validation... by Ashima Singh, Marci K Sontag, Mei Zhou, Mahua Dasgupta, Tessa Crume, Morgan McLemore, Najibah Galadanci, Eldrida Randall, Nicole Steiner, Amanda M Brandow, Kathryn Koch, Joshua J Field, Kathryn Hassell, Angela B Snyder, Julie Kanter

Get full text